RETRACTION

Connecting asciminib tolerability to long-term treatment persistence. Comment on: “Favorable tolerability of asciminib versus ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemia” by Chan Zhang

Retraction Notice due to paper mill activity for the paper:
Comment with doi https://doi.org/10.3324/haematol.2026.301608
Connecting asciminib tolerability to long-term treatment persistence. Comment on: “Favorable tolerability of asciminib versus ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemia”

The Comment with doi https://doi.org/10.3324/haematol.2026.301608 has been retracted by the Editor-in-Chief of Haematologica. For details on our editorial standards, please refer to the Haematologica policy on the misuse of Artificial Intelligence in submitted manuscripts (https://haematologica.org/our-policies).

This comment was found to be nearly identical to other comments submitted by different authors discussing various original articles in Haematologica. Following an internal investigation, it was determined that this contribution originated from a coordinated network and exhibited clear indicators of systematic manipulation (paper mill activity). The authors were contacted regarding these concerns but failed to respond. Consequently, the Editor concluded that the comment is non-authentic, standardized, and lacks legitimate scientific rationale. The authors have been formally notified of this retraction.

To whom correspondence should be addressed: office@haematologica.org

doi:10.3324/haematol.2026.302413